Egalet (EGLT) EPS Estimated At $-0.38; Orasure Technologies (OSUR) Sentiment Is 1.01

February 14, 2018 - By Louis Casey

OraSure Technologies, Inc., together with its subsidiaries, develops, makes, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company has market cap of $1.07 billion. It operates in two divisions, OSUR and DNAG. It has a 34.12 P/E ratio. The firm also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Analysts expect Egalet Corporation (NASDAQ:EGLT) to report $-0.38 EPS on March, 8.They anticipate $0.49 EPS change or 56.32% from last quarter’s $-0.87 EPS. After having $-0.46 EPS previously, Egalet Corporation’s analysts see -17.39% EPS growth. The stock decreased 1.25% or $0.0101 during the last trading session, reaching $0.7999. About 251,750 shares traded. Egalet Corporation (NASDAQ:EGLT) has declined 46.67% since February 14, 2017 and is downtrending. It has underperformed by 63.37% the S&P500.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions. The company has market cap of $36.72 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It currently has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

Investors sentiment decreased to 0.58 in Q3 2017. Its down 0.13, from 0.71 in 2017Q2. It dived, as 14 investors sold Egalet Corporation shares while 17 reduced holdings. 11 funds opened positions while 7 raised stakes. 20.27 million shares or 84.59% more from 10.98 million shares in 2017Q2 were reported. Moreover, Geode Mgmt Ltd Liability Com has 0% invested in Egalet Corporation (NASDAQ:EGLT). Moreover, California Employees Retirement has 0% invested in Egalet Corporation (NASDAQ:EGLT) for 28,500 shares. Wasatch Advisors Inc invested 0% of its portfolio in Egalet Corporation (NASDAQ:EGLT). Glenmede Tru Na has 0% invested in Egalet Corporation (NASDAQ:EGLT) for 150 shares. Tiverton Asset Management Limited Liability Corporation invested 0% of its portfolio in Egalet Corporation (NASDAQ:EGLT). Planning invested in 0% or 10,000 shares. Barclays Public Ltd Com holds 0% or 1,265 shares in its portfolio. J Goldman And L P invested in 0% or 100,000 shares. Janney Montgomery Scott Lc invested in 0% or 41,463 shares. Nj State Employees Deferred Compensation Plan invested 0.08% in Egalet Corporation (NASDAQ:EGLT). Vanguard Incorporated reported 1.13 million shares or 0% of all its holdings. Armistice Capital Lc reported 2.05M shares stake. Franklin Res holds 0% or 2.73M shares in its portfolio. Wells Fargo Mn holds 7,099 shares or 0% of its portfolio. Bridgeway Management Incorporated has 0% invested in Egalet Corporation (NASDAQ:EGLT) for 191,350 shares.

Among 5 analysts covering Egalet Ltd (NASDAQ:EGLT), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Egalet Ltd had 13 analyst reports since November 4, 2015 according to SRatingsIntel. The stock of Egalet Corporation (NASDAQ:EGLT) has “Hold” rating given on Wednesday, January 3 by Stifel Nicolaus. The firm earned “Buy” rating on Monday, September 11 by Cantor Fitzgerald. Cantor Fitzgerald initiated the shares of EGLT in report on Wednesday, November 4 with “Buy” rating. The stock of Egalet Corporation (NASDAQ:EGLT) earned “Buy” rating by Cantor Fitzgerald on Wednesday, November 8. The stock of Egalet Corporation (NASDAQ:EGLT) earned “Buy” rating by Cantor Fitzgerald on Wednesday, June 7. JMP Securities maintained Egalet Corporation (NASDAQ:EGLT) rating on Friday, July 14. JMP Securities has “Market Outperform” rating and $6 target. The firm has “Buy” rating given on Friday, June 9 by JMP Securities. Cantor Fitzgerald maintained the shares of EGLT in report on Thursday, June 1 with “Buy” rating. As per Monday, August 14, the company rating was maintained by Cantor Fitzgerald. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, June 13.

Domini Impact Investments Llc holds 15.53% of its portfolio in OraSure Technologies, Inc. for 30,359 shares. Daruma Capital Management Llc owns 2.57 million shares or 3.6% of their US portfolio. Moreover, Sanctuary Wealth Advisors Llc has 3.07% invested in the company for 176,010 shares. The Illinois-based Oberweis Asset Management Inc has invested 2.96% in the stock. Pier Capital Llc, a Connecticut-based fund reported 258,630 shares.

Since January 1, 0001, it had 0 buys, and 5 selling transactions for $1.36 million activity.

The stock increased 2.49% or $0.43 during the last trading session, reaching $17.71. About 194,266 shares traded. OraSure Technologies, Inc. (OSUR) has risen 116.07% since February 14, 2017 and is uptrending. It has outperformed by 99.37% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>